Condition
Diabetes Mellitus, Type 2
Locations
Australia, Germany, Hungary, Poland, Romania, Slovakia, Spain, United States
Start date
22/06/2026
Identifiers
Trial ID NN9559-8577,
NCT number NCT07668388,
Eudract number Not Available
NCT number NCT07668388,
Eudract number Not Available
Summary
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.
Trial Overview:
Treatment
DRUG: UBT251
DRUG: UBT251 Placebo
DRUG: Semaglutide
DRUG: Semaglutide Placebo
Study type
INTERVENTIONAL
Trial duration
Jun 22 2026 - Nov 15 2027
Participants
300
Phase
II
Are you eligible?
Gender
Male and female
Age
18 to 75 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.